Can aspirin reduce the risk of colorectal cancer in people with diabetes? A population-based cohort study

Diabetic Medicine

Volumn 32, Issue 3, 2015, Pages 324-331

  Lin, C C ^a,b   Lai, M S ^b   Shau, W Y ^c,d  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; INSULIN; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; COLORECTAL CANCER; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIABETIC PATIENT; DRUG USE; FEMALE; HEALTH INSURANCE; HEART INFARCTION; HEPATITIS B; HEPATITIS C; HOSPITALIZATION; HUMAN; INSULIN TREATMENT; LIVER DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH INSURANCE; PERIPHERAL VASCULAR DISEASE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; SENESCENCE; SENSITIVITY ANALYSIS; TREATMENT DURATION; AGED; COLORECTAL NEOPLASMS; COMPLICATION; DOSE RESPONSE; LONGITUDINAL STUDY; MIDDLE AGED; PREVALENCE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TAIWAN; TIME;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COHORT STUDIES; COLORECTAL NEOPLASMS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN; TIME FACTORS;

EID: 84922646116     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12596     Document Type: Article

References (30)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2011; 127: 2893-2917.
2. Bureau of Health Promotion. Cancer Registry Annual Report, 2009, Taiwan. Available at: http://www.bhp.doh.gov.tw/BHPNet/Web/Stat/StatisticsShow.aspx?No=201206210001. Last accessed 28 February 2013.
3. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33: 1674-1685.
4. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005; 97: 1679-1687.
5. Giouleme O, Diamantidis MD, Katsaros MG. Is diabetes a causal agent for colorectal cancer? Pathophysiological and molecular mechanisms. World J Gastroenterol 2011; 17: 444-448.
6. Limburg PJ, Vierkant RA, Fredericksen ZS, Leibson CL, Rizza RA, Gupta AK et al. Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective cohort study. Am J Gastroenterol 2006; 101: 1872-1879.
7. Ren X, Zhang X, Zhang X, Gu W, Chen K, Le Y et al. Type 2 diabetes mellitus associated with increased risk for colorectal cancer: evidence from an international ecological study and population-based risk analysis in China. Public Health 2009; 123: 540-544.
8. Elwing JE, Gao F, Davidson NO, Early DS. Type 2 diabetes mellitus: the impact on colorectal adenoma risk in women. Am J Gastroenterol 2006; 101: 1866-1871.
9. Yang YX, Hennessy S, Lewis JD. Type 2 diabetes mellitus and the risk of colorectal cancer. Clin Gastroenterol Hepatol 2005; 3: 587-594.
10. Berster JM, Göke B. Type 2 diabetes mellitus as risk factor for colorectal cancer. Arch Physiol Biochem 2008; 114: 84-98.
11. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48: 4399-4404.
12. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE et al. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007; 99: 608-615.
13. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Wu K, Fuchs CS. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 2008; 134: 21-28.
14. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005; 294: 914-923.
15. Ruder EH, Laiyemo AO, Graubard BI, Hollenbeck AR, Schatzkin A, Cross AJ. Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol 2011; 106: 1340-1350.
16. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009; 101: 256-266.
17. Flossmann E. Rothwell PM, on behalf of the British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007; 369: 1603-1613.
18. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, Meade TW. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376: 1741-1750.
19. National Health Research Institute. National Health Insurance Research Database, Taiwan. 2012. Available at: http://nhird.nhri.org.tw/en/Data_Subsets.html#S3. Last accessed 28 February 2013.
20. Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 2010; 340: b5087.
21. Shintani AK, Girard TD, Eden SK, Arbogast PG, Moons KG, Ely EW. Immortal time bias in critical care research: application of time-varying Cox regression for observational cohort studies. Crit Care Med 2009; 37: 2939-2945.
22. Pasternak B, Svanström H, Callréus T, Melbye M, Hviid A. Use of angiotensin receptor blockers and the risk of cancer. Circulation 2011; 123: 1729-1736.
23. Stürmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med 1998; 128: 713-720.
24. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE et al. Low-dose aspirin in the primary prevention of cancer (The Women's Health Study): a randomized controlled trial. JAMA 2005; 294: 47-55.
25. Ye X, Fu J, Yang Y, Chen S. Dose-Risk and Duration-Risk Relationships between Aspirin and Colorectal Cancer: A Meta-Analysis of Published Cohort Studies. PLoS One 2013; 8: e57578.
26. Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 2012; 23: 1403-1415.
27. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012; 13: 518-527.
28. Brasky TM, Potter JD, Kristal AR, Patterson RE, Peters U, Asgari MM et al. Nonsteroidal anti-inflammatory drugs and cancer incidence by sex in the VITamins And Lifestyle (VITAL) cohort. Cancer Causes Control 2012; 23: 431-444.
29. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM. Cyclooxygenases in cancer: progress and perspective. Cancer Lett 2004; 215: 1-20.
30. Mahipal A, Anderson KE, Limburg PJ, Folsom AR. Nonsteroidal anti-inflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev 2006; 15: 1785-1790.